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Identity 
Other names: EC 2.7.11.26 
HGNC (Hugo): GS3KB 
Location: 3q13.33 
Local order: 
Human: Nuclear receptor subfamily 1, group I, 
member 2 (NR1I2); GSK3B; G-protein coupled 
receptor 156 (GPR156).  
Mouse: G-protein coupled receptor 156 (Gpr156); 




According to Entrez-Gene, human GSK3B maps to 
locus NC_000003.11.  
This gene contains 12 exons that encompass 266971 bp 
of genomic DNA. In mice, GSK3B maps to 
NC_000082.5 and contains 11 exons that span 157079 
bp of DNA within the mouse genome. 
Transcription 
Human GSK3B mRNA (NM_002193.3) consists of 
7134 bp, and murine GSK3B mRNA (NM_019827) 
contains 8298 bp. Alternatively spliced transcript 
variants encoding different isoforms (1 and 2) have 
been found for human gene. Transcript variant 2 is 
missing an in-frame coding exon (9) compared to 
variant 1, resulting in a shorter isoform 2 lacking a 13 
aa segment compared to isoform 1. 
Pseudogene 
No pseudogene has been identified for GSK3B. 
 
A) Human GSK3B gene, isoform 1. B) Mouse Gsk3b gene. GSK3B is comprised of 12 exons in human and 11 exons in mouse. The 
ATG start codon is located within exon 1 and the TAG stop codon is found in exon 12 (Human) and 11 (Mouse). The sizes of exons for 
human gene 1-12 are 1071 bp, 191 bp, 85 bp, 110 bp, 130 bp, 106 bp, 97 bp, 95 bp, 38 bp, 186 bp, 98 bp and 604 bp, respectively. The 
sizes of exons for mouse gene 1-11 are 1613 bp, 193 bp, 83 bp, 110 bp, 130 bp, 106 bp, 97 bp, 95 bp, 186 bp, 98 bp and 5577 bp, 
respectively. 
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GSK3B structure. GSK3B is a 46-47 kDa protein consisting of 433 and 420 amino acids in human and mouse respectively. The protein 
contains an N-terminal domain, a kinase domain and a C-terminal domain. Phosphorylation of Tyr216 located in the T-loop (activation 
site) facilitates substrate phosphorylation by GSK3B but is not strictly required for its kinase activity. Phosphorylation of GSK3B at Ser9 in 
N-terminal region leads to inhibition of its kinase activity. Binding domain (BD) includes GSK3B specific binding sites for substrates and 




Glycogen synthase kinase-3 beta (GSK3B) was named 
due to its ability to phosphorylate and inactivate 
glycogen synthase. GSK3B is a multifunctional 
serine/threonine kinase which has been implicated in 
multiple biological processes including embryonic 
development, cell differentiation, apoptosis and insulin 
response. GSK3B is a key component in neuronal 
functions and has been implicated in major diseases 
involving the central nervous system. 
Expression 
GSK3B was originally isolated from the skeletal 
muscle but it is ubiquitously expressed in almost all the 
tissues. However, abundant expression is detected in 
brain tissue, especially in the neurons when compared 
to the astrocytes. The high level of expression in the 
brain is due to its vital role in the neuronal signaling. 
Dysregulation of GSK3B expression leads to various 
pathological conditions such as diabetes or insulin 
resistance, neuronal dysfunction and neuronal diseases. 
Localisation 
GSK3B is generally considered a cytosolic protein; 
however, it is reported to be present in the nucleus and 
mitochondria. Nuclear and mitochondrial localization 
of GSK3B correlates with its higher kinase activity 
compared to cytosolic protein. Translocation and 
specific cellular localization of GSK3B determine its 
involvement in signaling pathways, regulate its 
interaction with substrates and participation in protein 
complex formation, and influence gene expression and 
transcription. 
Function 
GSK3B is a multifunctional protein kinase which is 
implicated in a large number of cellular processes and 
diseases. GSK3B is regulated by serine (inhibitory) and 
tyrosine (activating) phosphorylation. More than 40  
 
 
proteins have been reported to be phosphorylated by  
GSK3B. GSK3B substrates include metabolic and 
signaling proteins like glycogen synthase, Acetyl CoA 
carboxylase, Axin, Cyclin D1; structural proteins like 
Tau, neural cell adhesion protein (NCAM); 
transcription factors like beta-catenin, p53, Myc, 
NFkappaB, CREB and AP-1; apoptotic-related proteins 
like Bax and p53. GSK3B also regulates various 
cellular processes by binding to protein complexes. 
Homology 
The GSK3B gene is conserved in human, chimpanzee, 
dog, cow, rat, chicken, zebrafish, fruit fly, mosquito, C. 
elegans, A. thaliana, rice, and P. falciparum. 
Mutations 
Germinal 
1. Several rare sequence variants in GSK3B were 
identified in the case-control study of patients with 
probable Alzheimer disease (AD), familial 
frontotemporal dementia (FTD), primary progressive 
aphasia, and aged healthy subjects. An intronic 
polymorphism (IVS2-68G>A) occurred at more than 
twice the frequency among patients with FTD (10.8%) 
and patients with AD (14.6%) than in aged healthy 
subjects (4.1%).  
2. GSK3beta promoter single-nucleotide polymorphism 
(rs334558) influences transcriptional strength, and the 
less active form was associated with less detrimental 
clinical features of mood disorders. Effect of rs334558 
was studied on grey matter volumes of patients affected 
by chronic schizophrenia. Carriers of the less active C 
allele variant showed significantly higher brain 
volumes in an area encompassing posterior regions of 
right middle and superior temporal gyrus, within the 
boundaries of Brodmann area 21. The temporal lobe is 
the brain parenchymal region with the most 
consistently documented morphometric abnormalities 
in schizophrenia, and neuropathological processes in 
these regions develop soon at the beginning of the 
illness. 










Ovarian cancer is a leading cause of death from 
gynecological malignancies. GSK3B promotes ovarian 
cancer cell proliferation by regulating Cyclin D1. 
GSK3B-dependent increased Cyclin D1 expression in 
ovarian cancer cells supports a possibility that GSK3B 
is involved in ovarian tumor chemotherapy resistance. 
Therefore, it is possible that combination of traditional 
chemotherapy and GSK3B inhibitors would benefit 
ovarian cancer patient response. 
Prostate cancer 
Note 
Androgen receptor (AR) regulates growth of normal 
and cancer prostate cells. AR phosphorylation status is 
associated with its transcriptional activation. GSK3B 
interacts directly with the AR, modulates AR signaling 
and plays important role in the control of the 
proliferation of normal and malignant androgen-
regulated tissues. Therefore, pharmacological inhibitors 
designed to increase GSK3B activity could be useful in 
prostate cancer therapy. 
Pancreatic cancer 
Note 
It was shown that pancreatic cancer cells contain a pool 
of active GSK3B, and that pharmacological inhibition 
of GSK3B kinase activity using small molecule 
inhibitors or genetic depletion of GSK3B by RNA 
interference leads to decreased cancer cell proliferation 
and survival. Hence GSK3B has potential as an 




Colon cancer cell lines and colon cells from colorectal 
cancer patients have higher levels of GSK3B 
expression than their normal counterparts. Inhibition of 
GSK3B activity either by chemical inhibitors or by 
expression by RNA interference targeting GSK3B 
induced apoptosis and attenuation of proliferation of 
colon cancer cells in vitro. Hence GSK3B has a 
potential as therapeutic target in colorectal cancer. 
Neuroblastoma 
Note 
Treatment of B65 neuroblastoma cell line with GSK3B 
inhibitors Lithium or SB415286 caused a decrease in 
cell proliferation that was associated with G2/M cell 
cycle arrest due to regulating the phosphorylation of 
Cdc2. Therefore, GSK3B and Cdc2 could be potential 




Glioblastoma is the most frequent malignant tumor of 
the brain and represents a subset of cancers that is 
mostly nonresponsive to currently available anticancer 
treatments.  
The current standard therapy for newly diagnosed 
glioblastoma consists of surgical resection of the tumor 
to the extent that is safe and feasible, followed by 
chemotherapy and irradiation. There has been an 
emerging paradigm for the combination of 
chemotherapy and molecular targeted therapy to 
improve therapeutic efficiency. Glioblastoma cells 
depend on deregulated GSK3B to survive, proliferate, 
and resist chemotherapy and radiation. Pretreatment 
with low-dose GSK3B inhibitor enhanced the cytocidal 
effect of ionizing radiation in glioblastoma cells. At the 
same time, GSK3B inhibitors have been shown to 
protect normal hippocampal neurons from radiation-
induced apoptosis. Therefore, GSK3B inhibition 
provides dual benefits for the glioblastoma patients 
treated with radiation: by attenuating tumor 
proliferation and by protecting host brain tissue from 
degradation and allowing its repair. 
Insulin resistance and diabetes 
Note 
Insulin resistance is caused by the inability of insulin 
sensitive tissues to respond to insulin and efficiently 
clear blood glucose. Insulin signaling involves 
autophosphorylation of the insulin receptor leading to 
the activation of PI3K which activates PKB (Akt). The 
activated PKB phosphorylates and inactivates GSK3B. 
Dysregulation of GSK3B results in impaired insulin 
signaling leading to diabetes. Inhibitors of GSK3B 




Alzheimer's disease (AD) is a chronic disorder that 
slowly destroys neurons and causes serious cognitive 
disability. The two neuropathologiocal features of 
Alzheimer's disease are neurofibrillary tangles and 
amyloid plaques. GSK3B has been implicated in both 
neuropathologies. In addition, presenilin 1 (PS1) have 
been linked to Alzheimer's disease. Presenilin 1 binds 
to and regulates GSK3B activity. Presenilin 1 
mutations might compromise neuronal function by 
increasing GSK3B activity. 
Schizophrenia 
Note 
Schizophrenia is a severe brain illness in which the 
disrupted in schizophrenia 1 (DISC1) gene is disrupted 
by a balanced chromosomal translocation. DISC1 is  
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highly expressed in neural progenitor cells and required 
for embryonic brain development. DISC1 regulates 
beta-catenin turnover by inhibiting GSK3B activity. 
GSK3B inhibitors are able to normalize progenitor 
proliferation and behavioral defects caused by DISC1 
loss of function. 
Bipolar affective disorder 
Note 
Patients with bipolar affective disorder have a history 
of experiencing manic episodes that are often 
interspersed with depression, and major depression is 
commonly referred to as mood disorders. Lithium, a 
known GSK3B inhibitor, is one of the most widely 
used mood-stabilizing agents for the treatment of 
bipolar disorder. 
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